Last mentioned: 5d ago
Across the most recent 6 stories covering Jefferies Financial Group — 100% neutral sentiment, averaging 5.3/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Wells Fargo Cuts Target to $70
Wells Fargo & Company lowers Freshpet’s price target from $75.00 to $70.00, keeping an Overweight rating, implying 28.42% upside.
Bank of America Lowers Target
Bank of America reduces its price target from $75.00 to $70.00 and maintains a Neutral rating.
Piper Sandler Stays Overweight
Piper Sandler reaffirms an Overweight rating on Freshpet shares.
Weiss Ratings Downgrades
Weiss Ratings cuts Freshpet from 'Hold (c)' to 'Hold (c-)'.
JPMorgan Upgrades, Others Reaffirm
JPMorgan raises rating from Neutral to Overweight and lifts target from $66.00 to $68.00. Morgan Stanley reiterates Overweight with $77.00 target, while Deutsche Bank holds at Hold with $63.00 target.
Jefferies Cuts Target
Jefferies Financial Group lowers its price objective from $75.00 to $70.00 and maintains a Hold rating.
TD Cowen Turns Bullish
TD Cowen upgrades Freshpet from Hold to Buy and sets an $80.00 price objective.
Oppenheimer Upgrades Freshpet
Oppenheimer raises Freshpet from Market Perform to Outperform with an $80.00 price target.
Wabtec guided revenue between $12.3-$12.6B and EPS slightly below the Street, while Moody’s EPS range also came in under estimates. Analysts remain constructive with moderate buy ratings and double-digit upside targets for both stocks.
Source: Bbns · Markets Daily
Monarch Casino & Resort posted a second-quarter earnings beat of $0.11 per share on revenue strength, driving the stock up 1.1% to $124.38. Valuation metrics remain solid with a P/E of 21.08 and a 1% dividend yield, but a recent CEO stock sale and mixed analyst ratings signal a cautious bias. Truist’s $144 price target offers the most bullish outlook, while Stifel sits at $102.
Source: MarketBeat · tickerreport.com
Wells Fargo lowered its price target on Freshpet to $70 from $75 while maintaining an Overweight rating, implying the stock is undervalued by 28%. The market remains skeptical with FRPT trading at $54.51, well below the consensus analyst target of $74.25. Analysts overall rate the pet food company a Moderate Buy, despite a string of recent target cuts.
Source: Watch List News · Ticker Report
A new Jefferies report warns that the massive AI infrastructure buildout is keeping U.S. inflation elevated, forcing markets to price in further rate hikes. Two-year Treasury yields just saw their biggest one-day jump in 14 months, and money markets now expect 36 basis points of tightening by year-end.
Zacks Research has issued rare 'Strong Sell' ratings for both Australian mining giant Fortescue and French luxury conglomerate Kering. The downgrades highlight deepening concerns over earnings estimate revisions and the companies' heavy exposure to a cooling Chinese economy.
Source: The Lincolnian Online · Bbns
AxoGen (NASDAQ: AXGN) has received a major boost from Wall Street as Wells Fargo upgraded the nerve-repair specialist to a 'Strong-Buy' rating. The upgrade follows a significant price target hike from Jefferies, signaling a robust consensus on the company's growth potential in the medical technology sector.
This page surfaces every story mentioning Jefferies Financial Group across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Jefferies Financial Group was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |